EKF Diagnostics launched its STAT-Site WB handheld analyzer, which delivers β-ketone and glucose measurements from whole blood in seconds, according to a news release from the company.
This follows the securing of its CE mark certification alongside its CLIA-waiver from the U.S. Food and Drug Administration (FDA), meaning that the portable, dual-purpose analyzer can be used by professionals in the management of diabetes patients.
The STAT-Site WB is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or BHB) and glucose in whole blood taken from capillary or venous samples.
The analyzer is reagent free, utilizing two different test strips to deliver results in just 10 seconds for β-ketones and 5 seconds for glucose. This enables clear and comprehensive management of diabetes patients displaying early symptoms of ketosis, ensuring their rapid treatment and subsequent regular monitoring.
βHB is used to aid the diagnosis and monitoring of patients with ketosis (diabetic ketoacidosis or DKA). As β-HB accounts for 78% of all ketones present in the body, and is the first to appear during ketosis, it provides the clearest indication of a patient’s condition before and after treatment, the company said.
